Preliminary assessment of celecoxib and microdiode pulse laser treatment of diabetic macular edema

Retina

Volumn 30, Issue 3, 2010, Pages 459-467

  Chew, Emily Y ^a   Kim, Jonghyeon ^b   Coleman, Hanna R ^a   Aiello, Lloyd Paul ^c   Fish, Gary ^d   Ip, Michael ^e   Haller, Julia A ^f,i   Figueroa, Maria ^b   Martin, Daniel ^g,j   Callanan, David ^d   Avery, Robert ^h   Hammel, Keri ^b   Thompson, Darby J S ^b   Ferris, Frederick L ^a  

^a NATIONAL EYE INSTITUTE   (United States)

^b EMMES CORPORATION   (United States)

^c JOSLIN DIABETES CENTER   (United States)

^d TEXAS RETINA ASSOCIATES   (United States)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g EMORY EYE CENTER   (United States)

^h California Retina Consultants   (United States)

ⁱ Will's Eye Philadelphia   (United States)

^j LERNER RESEARCH INSTITUTE   (United States)

more..

Author keywords

Celecoxib; Diabetic macular edema; Diode grid laser photocoagulation; ETDRS type focal photocoagulation; Optical coherence tomography

Indexed keywords

CELECOXIB; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIODE LASER; FEMALE; HUMAN; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL; RETINA FLUORESCEIN ANGIOGRAPHY; SYSTEMATIC REVIEW; VISUAL ACUITY; VISUAL IMPAIRMENT;

ADMINISTRATION, ORAL; CAPILLARY PERMEABILITY; COMBINED MODALITY THERAPY; CYCLOOXYGENASE 2 INHIBITORS; DIABETIC RETINOPATHY; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; LASERS, SOLID-STATE; MACULAR EDEMA; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; PYRAZOLES; RETINA; SULFONAMIDES; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY;

EID: 77949393585     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181bcf1a0     Document Type: Article

References (31)

1. The Eye Disease Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004;122:477-485.
2. The Eye Disease Prevalence Research Group. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004;122:552-563.
3. Klein R, Klein B, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 1984;91:1464-1474
4. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol 1985;103:1796-1806.
5. Schatz H, Maderia D, McDonald HR, Johnson RN. Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular edema. Arch Ophthalmol 1991;109:1549-1551.
6. Mainster MA. Decreasing retinal photocoagulation damage: principles and techniques. Semin Ophthalmol 1999;14:200-209.
7. Roider J. Laser treatment of retinal diseases by subthreshold laser effects. Semin Ophthalmol 1999;14:19-26.
8. Roider J, Brinkmann R, Wirbelauder C, Laqua H, Birngruber R. Subthreshold (retinal pigment epithelium) photocoagulation in macular diseases: a pilot study. Br J Ophthalmol 2000;84: 40-47.
9. Luttrull JK, Musch DC, Mainster MA. Subthreshold diode micropulse photocoagulation for the treatment of clinically significant diabetic macular edema. Br J Ophthalmol 2005;89: 74-80.
10. Sivaprasad S, Sandhu R, Tandon A, Sayed-Ahmed K, McHugh DA. Subthreshold micropulse diode laser photocoagulation for clinically significant diabetic macular oedema: a three-year follow-up. Clin Experiment Ophthalmol 2007;7: 640-644.
11. Johnson EI, Dunlop ME, Larkins RG. Increased vasodilatory prostaglandin production in the diabetic rat retinal vasculature. Curr Eye Res 1999;18:79-82.
12. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331: 1480-1487.
13. Joussen AM, Poulaki V, Mitsiades N, et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J 2002;16:438-440.
14. Amrite AC, Ayalasomayajula SP, Cheruvu NPS, Kompella UB. Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes induced elevations of retinal PGE2, VEGF, and vascular leakage. Invest Ophthalmol Vis Sci 2006; 47:1149-1160.
15. Sennlaub F, Valamanesh F, Vazquez-Tello A, et al. Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy. Circulation 2003;108:198-204.
16. Solomon SD, Wittes J, Finn PV, et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 2008;117:2104-2113.
17. Ferris FL, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol 1982;94: 91-96.
18. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1987;94:761-774.
19. Davis MD, Bressler SB, Aiello LP, et al. Comparison of time-domain OCT and fundus photographic assessments of retinal thickening in eyes with diabetic macular edema. Invest Ophthalmol Vis Sci 2008;49:1745-1752.
20. Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98: 807-822.
21. Solomon SD, McMurray JJV, Pfeffet MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-1080.
22. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear model. Biometrika 1986;73:13-22.
23. Zhao LP, Prentice RL. Correlated binary regression using a quadratic exponential model. Biometrika 1990;77:642-648.
24. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002;109:920-927.
25. The PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes 2005;54:2188-2197.
26. Cunningham ET, Adamis AP, Altaweel M. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005;112:1747-1757.
27. Cunningham ET Jr, Adamis AP, Altaweel M; Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005; 112:1747-1757.
28. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006;26:999-1005.
29. Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006;142:961-969.
30. Pendergast SD, Hassan TS, Williams GA, et al. Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid. Am J Ophthalmol 2000;130:178-186.
31. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008;115:1445-1446.